ACRS
ACRS
US00461U1051
Aclaris Therapeutics, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
563.77M EUR
739.67M EUR
523.7M EUR
362.7M EUR
Enterprise Value
468.18M EUR
720.5M EUR
495.04M EUR
342.74M EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-4.86x
--
--
--
Price to Sales
68.59x
90x
62.59x
56.93x
Price to Book
4.3x
5.94x
3.65x
3.52x
EV/Revenue
56.96x
87.66x
59.17x
53.8x
EV/EBITDA
-5.47x
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-7.44%
-8.41%
-9.82%
-9.18%
ende